Practice Matters

Oral Cancer Therapy: Policy Implications for the Uninsured and Underinsured Populations

Beth Faiman, CNP

From Cleveland Clinic, Cleveland, Ohio

Ms. Faiman has acted as a consultant for Celgene, Millennium, and Onyx Pharmaceuticals.

Correspondence to: Beth Faiman, CNP, Cleveland Clinic Foundation, 9500 Euclid Avenue R35, Cleveland, OH 44195. E-mail: faimanb@ccf.org


J Adv Pract Oncol 2013;4:354–360 | DOI: 10.6004/jadpro.2013.4.5.7 | © 2013 Harborside Press®


  

ABSTRACT

Approximately 25% of the nearly 400 anticancer drugs that are currently in development will be available in oral formulations. Yet in many states, while IV medications are reimbursed without substantial out-of-pocket costs to the patient, oral medications can be associated with excessive copays or not reimbursed at all.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.